We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.89%
2 Industrials 0.04%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
226
Karyopharm Therapeutics
KPTI
$43.5M
$12K ﹤0.01%
+53
New +$12.3K
CGEN icon
227
PUT
Compugen
CGEN
$222M
$6K ﹤0.01%
+500
New +$6.9K
CCXI
228
DELISTED
ChemoCentryx, Inc.
CCXI
$2K ﹤0.01%
37
– –
BLSA
229
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$1K ﹤0.01%
+100
New +$1.07K
ACAD icon
230
PUT
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-100,000
Closed -$4.13M
ADMA icon
231
ADMA Biologics
ADMA
$1.96B
– –
-200,000
Closed -$478K
AL
232
PUT
DELISTED
Air Lease Corp
AL
– –
-17,600
Closed -$518K
APLS
233
DELISTED
Apellis Pharmaceuticals
APLS
– –
-18,726
Closed -$565K
ARWR icon
234
CALL
Arrowhead Research
ARWR
$11.9B
– –
-150,000
Closed -$6.46M
ATRA icon
235
Atara Biotherapeutics
ATRA
$75.5M
– –
-17,072
Closed -$5.53M
BCLI
236
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-78,007
Closed -$19.8M
BMY icon
237
CALL
Bristol-Myers Squibb
BMY
$133B
– –
-300,000
Closed -$18.1M
BTAI icon
238
BioXcel Therapeutics
BTAI
$24.9M
– –
-170
Closed -$132K
CRBP icon
239
CALL
Corbus Pharmaceuticals
CRBP
$166M
– –
-7,337
Closed -$397K
CRNX icon
240
Crinetics Pharmaceuticals
CRNX
$8.84B
– –
-50,000
Closed -$784K
CYTK icon
241
PUT
Cytokinetics
CYTK
$10.5B
– –
-320,000
Closed -$6.93M
DTIL icon
242
Precision BioSciences
DTIL
$180M
– –
-294
Closed -$55K
HST icon
243
PUT
Host Hotels & Resorts
HST
$17.2B
– –
-400,000
Closed -$4.32M
IGMS
244
CALL
DELISTED
IGM Biosciences
IGMS
– –
-250,000
Closed -$18.5M
INCY icon
245
CALL
Incyte
INCY
$24.2B
– –
-150,000
Closed -$13.5M
INCY icon
246
PUT
Incyte
INCY
$24.2B
– –
-100,000
Closed -$8.97M
KOD icon
247
PUT
Kodiak Sciences
KOD
$2.6B
– –
-250,000
Closed -$14.8M
MCRB icon
248
Seres Therapeutics
MCRB
$46.8M
– –
-4,772
Closed -$2.79M
MDGL icon
249
CALL
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-114,900
Closed -$13.6M
MESO
250
PUT
Mesoblast
MESO
$1.84B
– –
-3,900
Closed -$145K
7 8 9
10
11

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.